Antidepressant Updates: Generics, VNS, & Serzone
Daniel Carlat, MD
Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
Read More
Michael J. Gitlin, M.D.
Professor of Clinical Psychiatry, UCLA School of Medicine
Director of the Mood Disorders Clinic, UCLA Neuropsychiatric Hospital
Dr. Gitlin has disclosed that he is a member of the speakers bureau of Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, Astra Zeneca, and Janssen. Dr. Gitlin has disclosed that psychostimulants, modafinil, and T3 have not been approved by the U.S. Food and Drug Administration for use in the treatment of depression.
Please consult product labeling for the approved usages.
Abraham Morgentaler, M.D.
Associate Clinical Professor of Urology,
Harvard Medical School
Author, The Viagra Myth
Dr. Morgentaler has disclosed that he is a member of the speakers bureau of Pfizer, Lilly/ICOS, Solvay, and Auxilium, that he is on the medical advisory boards of Solvay and Auxilium, and that he has a funded fellowship from Auxilium. Dr. Morgentaler has disclosed that testosterone has not been approved by the U.S. Food and Drug Administration for use in the treatment of depression. Please consult product labeling for the approved usage. 
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.webp?t=1729528747)



